Диссертация (1335938), страница 25
Текст из файла (страница 25)
– 2006. – №6. – P. 191–207.86.Debette S., Genetics of atherothrombotic and lacunar stroke /Seshadri S. //CircCardiovasc Genet. – 2009. – V. 2, №2. – P. 191–198.87.Del Zoppo G.J. Plasminogen Activators and Ischemic Stroke: Conditions forAcute Delivery // SeminThrombHemost. – 2013. – V. 39, №4. – P. 406–425.88.Denford S. Doctors’ understanding of individualisation of drug treatments: aqualitative interview study /Frost J., Dieppe P., Britten N.
// BMJ Open. – 2013. –V. 3, №5. – P. e002706.89.Di Sarsina P.R. Traditional, complementary and alternative medical systems andtheir contribution to personalisation, prediction and prevention in medicine—person-centred medicine /Alivia M.,Guadagni P. // EPMA J.– 2012. – V.3, №1. –P. 15.90.Dichgans M. Genetics of ischaemic stroke // Lancet Neurol. – 2007. – V. 6, №2.– P. 149-161.91.Donahue M.J. Novel MRI approaches for assessing cerebral hemodynamics inischemic cerebrovascular disease /Strother M.K., Hendrikse J.
// Stroke. – 2012. –V. 43, №3. – P. 903-915.92.Elkind M.S. Epidemiology and risk factors // Continuum (MinneapMinn). – 2011.– №17(6 2ndary Stroke Prevention). – P. 1213-1232.93.Ellis J.A. Endovascular treatment strategies for acute ischemic stroke/Youngerman B.E., Higashida R.T., Altschul D., Meyers P.M. // Int J of Stroke. –2011. – V. 6, №6. – P. 511-522.94.European Stroke Organisation (ESO) Executive Committee; ESO WritingCommittee. Guidelines for management of ischaemic stroke and transientischaemic attack // Cerebrovasc Dis.
– 2008. – №25. – P. 457 – 507.95.Evangelista F.C. Lack of association between potential prothrombotic genetic riskfactors and arterial and venous thrombosis/ Rios D.R., Ribeiro D.D., Carvalho156M.G., Dusse L.M., Fernandes A.P., Sabino A.P. // Genet Mol Res. 2015.V. 14,№3. P. 9585-9594.96.Ewan L.M. An observation-based intervention for stroke rehabilitation:experiences of eight individuals affected by stroke /Kinmond K., Holmes P.S. //DisabilRehabil. – 2010. – V. 32, №25. – P. 2097-2106.97.Feairheller D.L.
Fenty-Stewart N.M.Exercise Training, NADPH Oxidasep22phox Gene Polymorphisms, and Hypertension /Brown M.D., Park J.-Y.,Brinkley T.E., Basu S., Hagberg J.M., Ferrell R.E.// Med Sci Sports Exerc. –2009. –V. 41, №7. – P. 1421–1428.98.Fisher R., Delivering preventive, predictive and personalised cancer medicine forrenal cell carcinoma: the challenge of tumour heterogeneity/ Larkin J., SwantonC. // EPMA J.
– 2012. – V. 3, №1. – P. 1.99.Fujimoto H. Association of the manganese superoxide dismutase polymorphismwith vasospastic angina pectoris /Kobayashi H., Ogasawara K., Yamakado M.,Ohno M. // J Cardiol. – 2010. –V. 55, №2. – P. 205-210.100. Fung T.T. Mediterranean diet and incidence of and mortality from coronary heartdisease and stroke in women /Rexrode K.M., Mantzoros C.S., Hu F.B.//Circulation.
– 2009. – №119. – P. 1093–1100.101. García Carrasco D., Aboitiz Cantalapiedra J. Effectiveness of motor imagery ormental practice in functional recovery after stroke: a systematic review //Neurologia.–2013.Режимдоступа:URLhttp://www.ncbi.nlm.nih.gov/pubmed/23601759.102. Gefenas E.
Does the “new philosophy” in predictive, preventive and personalisedmedicine require new ethics? /Cekanauskaite A., Tuzaite E., Dranseika V.,Characiejus D. // EPMA J. – 2011. –V. 2, №2. – P. 141–147.103. Golubnitschaja O. European strategies in predictive, preventive and personalisedmedicine: highlights of the EPMA World Congress 2011 /Costigliola V. // EPMAJ. – 2011. – V. 2, №4. – P. 315–332.104.
Golubnitschaja O. General Report & Recommendations in Predictive, Preventiveand Personalised Medicine 2012: White Paper of the European Association for157Predictive, Preventive and Personalised Medicine /Costigliola V.// EPMA J. –2012. – V. 3, №1. – P. 14.105. González R.G. Clinical MRI of Acute Ischemic Stroke // J MagnReson Imaging.– 2012.
– V. 36, №2. – P. 259–271.106. Gretarsdottir S. Risk variants for atrial fibrillation on chromosome 4q25 associatewith ischemic stroke /Thorleifsson G., Manolescu A. // Ann Neurol. – 2008. –№64. – P. 402–409.107. Grunda T. Homonymous hemianopia and related visual defects: Restoration ofvision after a stroke /Marsalek P., Sykorova P. // ActaNeurobiolExp (Wars). –2013. – V. 73, №2.
– P. 237-249.108. Gu D.P. The incidence of co-morbidities related to obesity and overweight: asystematic review and meta-analysis /Zhang W., Bansback N., Amarsi Z.,Birmingham L., Anis A.H. //BMC Public Health. – 2009. – №9 – P. 88–90.109. Gudbjartsson D.F. A sequence variant in ZFHX3 on 16q22 associates with atrialfibrillation and ischemic stroke /Holm H., Gretarsdottir S. // Nat Genet. – 2009. –№41. – P. 876–878.110. Haapaniemi E. Is D-dimer helpful in evaluating stroke patients? A systematicreview /Tatlisumak T.// ActaNeurol Scand. – 2009. – V. 119, №3. – P.
141-150.111. Haeusler K.G., Laufs U., Endres M. Chronic heart failure and ischemic stroke //Stroke. – 2011. –V. 42, №10. – P. 2977-2982.112. Hankey G.J. Antithrombotic drugs for patients with ischaemic stroke andtransient ischaemic attack to prevent recurrent major vascular events /EikelboomJ.W. // Lancet Neurol. – 2010. – №9. – P. 273–284.113. Hanscombe K.B. METASTROKE Consortium; Wellcome Trust Case ControlConsortium 2, Williams F.M., Markus H.S., Lewis CM.
Genetic FactorsInfluencing Coagulation Factor XIII B-Subunit Contribute to Risk of IschemicStroke/ Traylor M., Hysi P.G., Bevan S., Dichgans M., Rothwell P.M., WorrallB.B., Seshadri S., Sudlow C // Stroke. 2015. V. 46, №8. P. 2069-2074.114. Hassan A. Genetics and ischaemic stroke /Markus H.S. // Brain. – 2000. – V. 123,№9. – P. 1784-1812.158115.
Heckman M.G. Genetic variants associated with myocardial infarction in thePSMA6 gene and Chr9p21 are also associated with ischaemic stroke /SotoOrtolaza A.I., Diehl N.N., Rayaprolu S., Brott T.G., Wszolek Z.K., Meschia J.F.,Ross O.A. // Eur J Neurol. – 2013. – V. 20, №2. – P. 300-308.116.
Heinemann V. Targeted therapy in metastatic colorectal cancer - An example ofpersonalised medicine in action /Douillard J.Y., Ducreux M., Peeters M. //CancerTreat Rev.– 2013. –V. 39, №6. – P. 592-601.117. Hisham N.F. Epidemiology, Pathophysiology, and Treatment of Hypertension inIschaemic Stroke Patients /Bayraktutan U.// J Stroke Cerebrovasc Dis. – 2012. Т22. – V. 7 – Р.
e4-e14.118. Khan T.A. Apolipoprotein E genotype, cardiovascular biomarkers and risk ofstroke: Systematic review and meta-analysis of 14 015 stroke cases and pooledanalysis of primary biomarker data from up to 60 883 individuals /Shah T., PrietoD., Zhang W., Price J. // Int J Epidemiol. – 2013. – V. 42, №2. – P. 475-492.119. Kraft P. Acute ischemic stroke: new approaches to antithrombotic treatment/Nieswandt B., Stoll G., Kleinschnitz C. // Nervenarzt.
– 2011. – №83. – P. 435–449.120. Kubo M. Genetic risk factors of ischemic stroke identified by a genome-wideassociation study // Brain Nerve. – 2008. – V. 60, №11. – P. 1339-1346.121. Kuklina E.V. Epidemiology and prevention of stroke: a worldwide perspective/Tong X., George M.G., Bansil P. // Expert Rev Neurother. – 2012. –V. 12, №2. –P.
199-208.122. Ladner T.R. Genetics of Cerebral Vasospasm /Zuckerman S.L., Mocco J. //Neurol Res Int. – 2013. – P. 291895.123. Lazaridou A. Yoga and Mindfulness as Therapeutic Interventions for StrokeRehabilitation: A Systematic Review /Philbrook P., Tzika A.A. // Evid BasedComplement Alternat Med. – 2013. – P. 357108.124. Lee M.-S. Personalized Medicine in Cardiovascular Diseases /Flammer A.J.,Lerman L.O., Lerman A. // Korean Circ J.– 2012.
– V.42, №9. – P. 583–591.159125. Lees K.R. Time to treatment with intravenous alteplase and outcome in stroke:An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHETtrials /Bluhmki E., Kummer R. // Lancet. – 2010. – №375. – P. 1695–1703.126. Leyden J.M. Adelaide stroke incidence study: declining stroke rates but manypreventable cardioembolic strokes /Kleinig T.J., Newbury J., Castle S., CranefieldJ., Anderson C.S., Crotty M., Whitford D., Jannes J., Lee A., Greenhill J.//Stroke.– 2013.
– V. 44, №5. – Р. 1226-1231.127. Lin H.F. Demethylation of Circulating Estrogen Receptor Alpha Gene in CerebralIschemic Stroke /Hsi E., Liao Y.C., Chhor B., Hung J., Juo S.H., Lin R.T. //PLoSOne.2015.V.10, №9. e0139608.128. Lindgren A. Stroke genetics: a review and update // J Stroke. 2014. -V.16, -№3.P. 114-123.129.
Liu M.E. A functional polymorphism of PON1 interferes with microRNA bindingto increase the risk of ischemic stroke and carotid atherosclerosis /Liao Y.C., LinR.T., Wang Y.S., Hsi E., Lin H.F., Chen K.C., Juo S.H. // Atherosclerosis. –2013. – V. 228, №1. – P. 161-167.130. Loos R.J. Genetic determinants of common obesity and their value in prediction //Best Pract Res ClinEndocrinolMetab. – 2012. – V.
26, №2. – P. 211-226.131. Lushchyk U.B. Predictive and preventive strategies to advance the treatments ofcardiovascular and cerebrovascular diseases: the Ukrainian context /NovytskyyV.V., Babii I.P., Lushchyk N.G., Riabets L.S. // EPMA J.– 2012. – V.3, №1. – P.12.132.
Macintosh B.J. Magnetic resonance imaging to visualize stroke and characterizestroke recovery: a review /Graham S.J. // Front Neurol. – 2013. –V. 27, №4. – P.60.133. Malyutina S. Relation between heavy and binge drinking and all-cause andcardiovascular mortality in Novosibirsk, Russia: a prospective cohort study/Bobak M., Kurilovitch S., Gafarov V., Simonova G., Nikitin Y., MarmotM.//Lancet. – 2002. – №360. – P. 1448–1454.160134. Markus H.S. Stroke genetics: prospects for personalized medicine // BMC Med. –2012. – №10.
– P. 113.135. Markus H.S. Evidence HDAC9 Genetic Variant Associated With Ischemic StrokeIncreases Risk via Promoting Carotid Atherosclerosis /Mäkelä K.M., Bevan S.,Raitoharju E., Oksala N., Bis J.C., O'Donnell C., Hainsworth A., Lehtimäki T. //Stroke. – 2013. – V. 44, №5. – P. 1220-1225.136. Mazzone T.
Cardiovascular disease risk in type 2 diabetes mellitus: insights frommechanistics studies /Chait A., Plutzky J. // Lancet. – 2008. – №371. – P. 1800–1809.137. McCourt C.M. Immunohistochemistry in the era of personalised medicine /BoyleD., James J., Salto-Tellez M. // J ClinPathol. – 2013. – V.
66, №1. – P. 58-61.138. Meschia J.F. New Information on the Genetics of Stroke // CurrNeurolNeurosciRep. – 2011. – V. 11, №1. – P. 35–41.139. Mesko B. The triad of success in personalised medicine: pharmacogenomics,biotechnology and regulatory issues from a Central European perspective/Zahuczky G., Nagy L. // N Biotechnol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
